SmarTrend(R) News Watch: Teva Stops Shipments on Generic Birth Control Pending Infringement Case
TEVA | Quote | Chart | News | PowerRating -- Teva Pharmaceutical Industries (NASDAQ:TEVA) said Tuesday that it has agreed to halt shipments of generic versions of Johnson & Johnson's (NYSE: JNJ | Quote | Chart | News | PowerRating) Ortho Tri-Cyclen Lo birth control pill. Shipments of the drugs will be suspended pending a preliminary injunction hearing in the patent infringement case with Johnson & Johnson scheduled to begin on July 15,2009. Teva Pharmaceutical Industries is a leading generic pharmaceutical company based in Israel, with 80% of sales from North America and Europe.
Write to Chip Brian at cbrian@tradethetrend.com
---------------------------------------------------------------------------------------------
SmarTrend analyzes over 5,000 securities simultaneously throughout the trading day and provides its subscribers with trend change alerts in real time. To get a free trial of our trading calls and maximize your trading results, please visit http://www.TradeTheTrend.com.
Get exclusive, actionable insight into how the market is expected to trend prior to market open with our free morning newsletter. Sign up at: http://www.TradeTheTrend.com/signup.html
For full details on Johnson & Johnson (JNJ) JNJ. Johnson & Johnson (JNJ) has Short Term PowerRatings at TradingMarkets. Details on Johnson & Johnson (JNJ) Short Term PowerRatings is available at This Link.
For full details on Teva Pharm Ind (TEVA) TEVA. Teva Pharm Ind (TEVA) has Short Term PowerRatings at TradingMarkets. Details on Teva Pharm Ind (TEVA) Short Term PowerRatings is available at This Link.
- Israeli Teva gets rights for multiple sclerosis drug in Nordic, Baltic states - 02/09/10
- Teva Pharmaceutical Industries: The Trend Continues Higher (TEVA) - 02/09/10
- BiomedReports: News and FDA Updates for Synta (NASDAQ:SNTA), Teva (NASDAQ:TEVA), Active Biotech (NASDAQ:ACTI) - 02/09/10
- Teva and Active Biotech amend marketing and distribution agreement - 02/09/10
- FDA Accepts Teva's XM02 for Neutropenia - 02/09/10
- More News >>


